|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
This study shows that there was no association between the polymorphism rs11200638 in HTRA1 gene and response to anti-VEGF treatment of exudative AMD.
|
28637435 |
2017 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
We confirmed the association of age-related maculopathy susceptibility 2 (ARMS2) rs10490924 (P=7.38 × 10<sup>-17</sup>), HTRA1 rs11200638 (P=5.47 × 10<sup>-17</sup>) and complement factor H gene (CFH) rs800292 (P=2.53 × 10<sup>-8</sup>) with neovascular AMD, all loci passing the genome-wide significance level (P<5.22 × 10<sup>-8</sup>).
|
28703135 |
2017 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
Rs12153855C and rs9391734A alleles could further increase the susceptibility to AMD in subjects with rs800292, rs11200638 and rs429608 risk alleles.
|
26861912 |
2016 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, the rs11200638-rs2672598 joint genotype AA-CC conferred higher risk to exudative AMD (43.11 folds) than PCV (3.68 folds).
|
27338780 |
2016 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
Eight single nucleotide polymorphisms (SNPs) from 6 genes of the HDL metabolism pathway and 2 known AMD-associated SNPs, rs800292 (from complement factor H [CFH]) and rs11200638 (from HtrA serine peptidase 1 [HTRA1]), were genotyped in all study subjects using the TaqMan genotyping technology (Applied Biosystems, Foster City, CA).
|
24393350 |
2014 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
FPR1 rs78488639 interacted with CFH rs800292, HTRA1 rs11200638, and smoking, enhancing risk to exudative AMD and PCV.
|
25277308 |
2014 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
The association of SKIV2L rs429608 with neovascular AMD remained significant after adjusting for CFH rs800292 and HTRA1 rs11200638.
|
23260260 |
2013 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
Genotypes of 3 polymorphisms in known AMD susceptibility loci (rs1061170 in complement factor H (CFH), rs11200638 in HTRA1 and rs1413711 in VEGF) were determined.
|
24080590 |
2013 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
Significant associations with both exudative AMD and PCV were observed in 11 of them and HTRA1 rs11200638</span>, with different genotypic distributions between exudative AMD and PCV (P < 0.001).
|
22491416 |
2012 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
We genotyped two SNPs that are located in the LOC387715 locus (rs10490924) and HTRA1 (rs11200638) in 137 cases of exudative AMD and 187 controls.
|
20456446 |
2010 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
We observed that homozygous risk genotypes (TT in rs10490924 and AA in rs11200638) were more strongly associated with AMD than the heterozygous genotypes (GT in rs10490924 and geographic atrophy in rs11200638) for both SNPs.
|
19491722 |
2009 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
The ORs of exudative AMD for individuals carrying one copy risk allele and two copy risk alleles were 2.57 (1.21 - 5.45) and 4.76 (2.15 - 10.55) respectively, with correspondent PARs of 28.3% (2.0% - 40.5%) and 38.2% (21.8% - 45.4%). rs11200638 in HTRA1 was another susceptible locus for AMD and the risk homozygotes were significantly susceptible for exudutive AMD (OR = 3.98, 1.88 - 8.43) with PAR of 38.9% (24.3% - 45.8%).
|
19187590 |
2008 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
Many single-nucleotide polymorphisms (SNPs), including the previously reported variants rs10490924 (hypothetical LOC387715/ARMS2) and rs11200638 (HTRA1), defined 2 significant haplotypes associated with increased risk of neovascular AMD.
|
18164066 |
2008 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
There was no significant difference in the incidence of CFH Y402H (P = 0.598) and HTRA1 rs11200638 (P = 0.290) between eyes with typical exudative AMD and with PCV.
|
18939352 |
2008 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
The HTRA1 promoter polymorphism, rs11200638, is a strong candidate with a functional consequence that predisposes Japanese to develop neovascular AMD.
|
17438519 |
2007 |
|
rs11200638
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.100 |
GeneticVariation |
BEFREE |
Homozygotes for the risk allele at rs11200638 had a 6.33-fold increased risk of PCV and a 13.77-fold increased risk of wet AMD when compared with homozygotes for the wild-type allele.
|
17692272 |
2007 |
|
rs2672598
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results revealed that HTRA1 rs2672598 is more significantly associated with exudative AMD than PCV in ARMS2/HTRA1 region, and it is responsible for elevated HTRA1 transcriptional activity and HTRA1 protein expression.
|
27338780 |
2016 |
|
rs2293870
|
HTRA1;LOC105378525
|
Glycogen storage disease type II
|
|
0.010 |
GeneticVariation |
BEFREE |
The coding HTRA1 SNP rs2293870, not part of the significant haplotypes containing rs10490924 and rs11200638, showed as strong an association with increased susceptibility to neovascular AMD.
|
18164066 |
2008 |